Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Seminars in Oncology

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.seminoncol.2011.11.002PMID 22289492
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

  2011cited by this paper
• BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

  2010cited by this paper
• Bosutinib.

  2010cited by this paper
• Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

  2009cited by this paper
• Harmonization of molecular monitoring of CML therapy in Europe

  2009cited by this paper
• Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

  2009cited by this paper
• Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.

  2009cited by this paper
• The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

  2009cited by this paper
• Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

  2009cited by this paper
• Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.

  2009cited by this paper
• Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR

  2009cited by this paper
• A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

  2009cited by this paper
• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  2009cited by this paper
• Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

  2009cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cited by this paper
• Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

  2008cited by this paper
• Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

  2008cited by this paper
• BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

  2008cited by this paper
• Quantitative monitoring of cell clones carrying point mutations in the BCR–ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD–PCR)

  2008cited by this paper
• Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

  2008cited by this paper
• Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

  2008cited by this paper
• ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

  2008cited by this paper
• Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR

  2008cited by this paper
• High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.

  2008cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008cited by this paper
• Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

  2007cited by this paper
• RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

  2007cited by this paper
• Chronic myeloid leukaemia.

  2007cited by this paper
• Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

  2007cited by this paper
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

  2007cited by this paper
• Chronic myeloid leukaemia as a model of disease evolution in human cancer

  2007cited by this paper
• High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations

  2007cited by this paper
• Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

  2007cited by this paper
• High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

  2007cited by this paper
• The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

  2006cited by this paper
• Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.

  2006cited by this paper
• Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

  2006cited by this paper
• The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.

  2006cited by this paper
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2006cited by this paper
• Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

  2006cited by this paper
• Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

  2006cited by this paper
• Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors

  2005cited by this paper
• Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

  2005cited by this paper
• High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

  2005cited by this paper
• Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

  2005cited by this paper
• Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment.

  2005cited by this paper
• Punish the parent not the progeny.

  2005cited by this paper
• Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

  2005cited by this paper
• Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL

  2005cited by this paper
• The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

  2005cited by this paper
• Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients.

  2005cited by this paper
• Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

  2004cited by this paper
• The biology of CML blast crisis.

  2004cited by this paper
• Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

  2004cited by this paper
• Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.

  2004cited by this paper
• Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

  2004cited by this paper
• Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

  2004cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

  2003cited by this paper
• Chronic myeloid leukemia--advances in biology and new approaches to treatment.

  2003cited by this paper
• Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

  2003cited by this paper
• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

  2002cited by this paper
• High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  2002cited by this paper
• Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2

  2002cited by this paper
• BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Alterations of P53 and RB Genes and the Evolution of the Accelerated Phase of Chronic Myeloid Leukemia

  2000cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.

  1995cited by this paper
• p53 in chronic myelogenous leukemia in acute phase.

  1991cited by this paper
• Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.

  1991cited by this paper
• Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia.

  1991cited by this paper
• Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia

  1991cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

  1989cited by this paper

• A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands

  2022cites this paper
• Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy

  2022cites this paper
• Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia

  2018cites this paper
• PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells

  2018cites this paper
• The role of protein-tyrosine phosphatases for sensitivity and resistance of CML-cells to tyrosine-kinase inhibitors

  2018cites this paper
• Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq

  2017cites this paper
• ROLE OF EXOSOMES RELEASED BY CHRONIC MYELOGENOUS LEUKEMIA CELLS IN THE CROSS-TALK WITH ENDOTHELIAL CELLS

  2017cites this paper
• A New Mutation Identified in an Imatinib and Nilotinib Resistant ChronicMyeloid Leukemia Patient

  2016cites this paper
• Flow immunophenotyping features of crisis phase of chronic myeloid leukemia in childhood: do we really care?

  2016cites this paper
• Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.

  2016cites this paper
• Treatment of chronic myelogenous leukemia.

  2016cites this paper
• Myeloproliferative Syndromes and Thrombocythemia

  2016cites this paper
• Multi-Drug Resistant Chronic Myeloid Leukemia: Report of Two Cases and Review of Literature

  2016cites this paper
• Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches

  2016cites this paper
• Chemopreventive Effects of Dietary Eicosapentaenoic Acid Supplementation in Experimental Myeloid Leukemia

  2015cites this paper
• Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients

  2015cites this paper
• Targeting FLT3 to treat leukemia

  2015cites this paper
• P210T315I-BCR/ABL转基因小鼠模型的建立与鉴定

  2015cites this paper
• Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

  2015cites this paper
• Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations

  2014cites this paper
• Ovarian minimal residual disease in chronic myeloid leukaemia.

  2014cites this paper
• BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein

  2014cites this paper
• Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy

  2014cites this paper
• Sequence analysis of the NUMB gene in chronic myeloid leukaemia patients

  2014cites this paper
• Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations

  2014cites this paper
• Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

  2014cites this paper
• Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.

  2014cites this paper
• Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

  2014cites this paper
• Systematic screen of chemotherapeutics in Drosophila stem cell tumors

  2014influential citation
• Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia

  2014cites this paper
• New insights in myeloid malignancies: application of massive genomics approaches for diagnosis and monitoring

  2014cites this paper
• Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations

  2014cites this paper
• Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations

  2014cites this paper
• Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations

  2014cites this paper
• Detection of ABL1 kinase mutations in Philadelphia‐positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single‐center experience in Korea

  2013cites this paper
• SIAH proteins: critical roles in leukemogenesis

  2013cites this paper
• The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-α in CML cell line, KT-1 cells.

  2013cites this paper
• Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells

  2013cites this paper
• Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.

  2013cites this paper
• Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes.

  2013cites this paper
• Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

  2013cites this paper
• Hematopoietic Stem Cells in Chronic Myeloid Leukemia

  2013influential citation
• ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia

  2013cites this paper
• Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

  2013cites this paper
• Bosutinib in the management of chronic myelogenous leukemia

  2013cites this paper
• Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.

  2013cites this paper
• Bosutinib in the management of chronic myelogenous leukemia

  2013cites this paper
• Genetics of chronic myeloid leukemia

  2013cites this paper
• Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

  2013cites this paper
• Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop

  2013cites this paper
• Including Rationalizations of Tumor-Associated Normative Notions in Pathophysiologic Considerations: Communication-Theoretical Implications

  2013cites this paper
• Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.

  2013cites this paper
• Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?

  2013cites this paper
• The impact of molecular biology techniques on the management of newly diagnosed chronic myeloid leukemia patients in chronic phase. A review.

  2013cites this paper
• The lost intrinsic fragmentation of MAT1 protein during granulopoiesis promotes the growth and metastasis of leukemic myeloblasts

  2013cites this paper
• Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.

  2013cites this paper
• Bosutinib in the management of chronic myelogenous leukemia

  2013cites this paper
• Immunomodulatory Effects of Tyrosine Kinase Inhibitors

  2013cites this paper
• Resistance revealed in acute lymphoblastic leukemia

  2013cites this paper
• ABL1 mRNA LEVELS IN PANCREATIC CANCER AND CHRONIC PANCREATITIS

  2012cites this paper
• Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors

  2012cites this paper
• DIFFERENTIAL SENSITIVITY TO UNRELATED ALK INHIBITORS

  2012cites this paper
• New and established tyrosine kinase inhibitors for chronic myeloid leukemia.

  2012cites this paper
• Cancer treatment according to BRCA1 and BRCA2 mutations

  2012cites this paper
• [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

  2012cites this paper